Immatics N.V.
As of Oct 22, 2026, Immatics is in Stage 4, the downtrend phase, now in week 14 (since Jul 22, 2026). It closed at $7.54, 36.5% below its 52-week high and below its 200-day average, which is falling.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IMTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IMTX among Biotechnology279th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …279 | IMTX | Stage 4 · wk 14 | 34 | −12.3% |
Immatics: quick answers
What stage is Immatics in?
As of Oct 22, 2026, Immatics (IMTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 22, 2026 and is in week 14. What the four stages mean
Is Immatics in an uptrend?
No. Immatics is in a Stage 4 downtrend. It trades 21.9% below its 200-day average, which is falling.
How far is Immatics from its 52-week high?
Immatics closed at $7.54 on Oct 22, 2026, 36.5% below its 52-week high of $11.87. Its 52-week low is $6.73.
How has Immatics performed over the past year?
As of Oct 22, 2026, Immatics is down 28.4% over the past year and down 27.8% so far in 2026.
Which sector and industry is Immatics in?
Immatics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.